Skip to main content

Table 4 The m6A protein alterations are correlated with clinicopathological features

From: Mechanism of RNA modification N6-methyladenosine in human cancer

Cancer Regulator Alteration Prognosis Metastasis/Invasion Tumor size Tumor stage Histological grade Recurrence Therapy Refs
AML METTL3/ WTAP Overexpression Poor        [41, 43]
AML METTL3/METTL14/YTHDF1/YTHDF2/FTO/ALKBH5 Mutation Poor        [142]
GBM METTL3 Overexpression Poor       Radioresistance [48]
GBM WTAP/RBM15/YTHDF1/ ALBKH5 Overexpression Poor     Increase    [49]
LC METTL3 Overexpression Poor Lymph node metastasis Brain metastasis Increase Worsen     [54, 55]
LC FTO/ IGF2BP1 Overexpression Poor        [56, 59]
HCC METTL3/YTHDF1 Overexpression Poor    Worsen     [58, 121]
HCC KIAA1429/ IGF2BP1 Overexpression Poor        [59, 63]
HCC WTAP Overexpression Poor      Prone   [64]
HCC METTL14 Down-regulation Better    Weaken Decrease    [100]
HCC YTHDF2 Overexpression Poor Microvascular invasion   Worsen     [65]
CRC METTL3 Overexpression Poor Lymph node metastasis Liver metastasis Distant metastasis     Prone Chemotherapy resistance [67, 68, 70]
CRC METTL3 Down-regulation Better   Decrease      [103]
CRC METTL14 Down-regulation Better    Weaken Decrease    [104]
CRC FTO Overexpression Poor   Increase Worsen     [71]
CRC YTHDC2 Overexpression Poor Lymph node metastasis   Worsen     [74]
CRC YTHDF1 Overexpression Poor Lymph node metastasis Distant metastasis   Worsen     [75]
CRC IGF2BP2 Overexpression Poor        [77]
PDAC METTL3 Overexpression Poor    Worsen     [78]
GC METTL3 Overexpression Poor        [80]
BCA METTL3 Overexpression Poor    Worsen Increase    [82]
BCA METTL14 Down-regulation Better    Weaken     [106]
PCA YTHDF2 Overexpression Poor     Increase    [85]
RCC METTL3 Down-regulation Better   Decrease   Decrease    [107]
RCC FTO Down-regulation Better    Weaken     [108]
RCC WTAP Overexpression Poor   Increase Worsen     [87]
CSCC FTO Overexpression Poor    Worsen Increase    [88]
BC METTL3 Overexpression Poor        [143]
BC FTO Overexpression Poor     Increase    [94]
EOC METTL3 Overexpression Poor    Worsen Increase    [95]
EOC ALKBH5 Overexpression Poor    Worsen Increase    [96]
EOC IGF2BP1 Overexpression Poor        [59]
Melanoma FTO Overexpression Poor    Worsen     [97]
Melanoma YTHDF1 Down-regulation Better    Weaken     [110]
  1. AML acute myeloid leukemia; GBM glioblastoma; LC lung cancer; HCC hepatocellular carcinoma; CRC colorectal cancer; PDAC pancreatic cancer; GC gastric carcinoma; BCA bladder cancer; PCA prostate cancer; RCC renal cell carcinoma; CSCC cervical squamous cell carcinoma; BC breast cancer; EOC epithelial ovarian cancer